Gibson Dunn advises Gyre Therapeutics, Inc. on $300 million acquisition of Cullgen Inc.

Gibson Dunn represented Gyre Therapeutics, Inc. in its definitive agreement to acquire Cullgen Inc. in an all-stock transaction valued at approximately $300 million, announced on March 3, 2026.
Under the terms of the agreement, Cullgen will become a wholly owned subsidiary of Gyre, and the transaction is expected to close early in the second quarter of 2026, subject to customary closing conditions and necessary regulatory approvals in the United States.
The acquisition will combine Gyre’s commercial-stage fibrosis business with Cullgen’s targeted protein degradation and degrader-antibody conjugate platform, creating a fully integrated biopharmaceutical company with U.S.- and China-based capabilities across discovery, manufacturing, and commercialization.

Gibson Dunn represented Gyre Therapeutics, Inc. in its definitive agreement to acquire Cullgen Inc. in an all-stock transaction valued at approximately $300 million, announced on March 3, 2026.
Under the terms of the agreement, Cullgen will become a wholly owned subsidiary of Gyre, and the transaction is expected to close early in the second quarter of 2026, subject to customary closing conditions and necessary regulatory approvals in the United States.
The acquisition will combine Gyre’s commercial-stage fibrosis business with Cullgen’s targeted protein degradation and degrader-antibody conjugate platform, creating a fully integrated biopharmaceutical company with U.S.- and China-based capabilities across discovery, manufacturing, and commercialization.

Deal Overview